SenzaGen’s Annual Report 2023 published

SenzaGen has today published its 2023 Annual Report. A digital copy can be downloaded at www.senzagen.com or read via the link below.

To request a printed copy, please email name and address to [e-mail].

Contacts

---

Peter Nählstedt, President and CEO, SenzaGen AB
Email: [e-mail] | Mobile: [phone]

Tina Dackemark Lawesson, VP Marketing & Communications
Email: [e-mail] | Mobile: [phone]

About us

---

SenzaGen is a corporate group that aims to be a leader in in vitro science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser. 

Attachments

---

SenzaGen Annual Report 2023

© Modular Finance, source Nordic Press Releases